萊茵生物(002166.SZ):2019年淨利預增0%-30%
格隆匯1月20日丨萊茵生物(002166.SZ)披露2019年年度業績預告,公司預計2019年1-12月實現歸屬於上市公司股東的淨利潤8166.43萬元-1.06億元,同比增長0%-30%。業績變動原因説明:
2019年度,公司預計報告期內合併營業收入增長近20%,其中特別是植物提取業務發展勢頭良好,營業收入大幅增長近30%,且毛利率提升,在公司各項費用保持平穩的情況下,使得公司2019年度經營業績較上年實現增長。2019年度公司BT項目已進入尾聲階段,但公司植物提取業務的增長已逐步彌補BT項目利潤減少對公司業績造成的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.